Michael Trautmann

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Daniel J. Drucker, John B. Buse, Kristin Taylor et al. · The Lancet · 2008 · 1.1K citations

Non-pharmacological Intervention, Diabetes Management, Insulin Management +7

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Dennis Kim, Leigh MacConell, Dongliang Zhuang et al. · Diabetes Care · 2007 · 445 citations · Full text

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 442 citations · Full text

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Michael A. Nauck, Santiago Durán, D. Kim et al. · Diabetologia · 2006 · 439 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +8

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Michaëla Diamant, Luc Van Gaal, Stephen Stranks et al. · The Lancet · 2010 · 435 citations

Diabetes Management, Insulin Glargine, Insulin Management +9